Plasma Nevirapine Levels and 24‐Week Efficacy in HIV‐Infected Patients Receiving Nevirapine‐Based Highly Active Antiretroviral Therapy with or without Rifampicin
Open Access
- 15 July 2006
- journal article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 43 (2) , 253-255
- https://doi.org/10.1086/505210
Abstract
Seventy human immunodeficiency virus (HIV)—infected patients receiving rifampicin and 70 HIV-infected patients not receiving rifampicin were enrolled to receive 400 mg of nevirapine-based highly active antiretroviral therapy per day. Mean plasma nevirapine levels at 8 and 12 weeks were lower in patients receiving rifampicin (P = .048). However, virological and immunological outcomes at 24 weeks were not different between the 2 groups (P > .05).Keywords
This publication has 7 references indexed in Scilit:
- Safety and tolerability of nevirapine-based antiretroviral therapy in HIV-infected patients receiving fluconazole for cryptococcal prophylaxis: a retrospective cohort studyBMC Infectious Diseases, 2005
- Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN StudyThe Lancet, 2004
- Nevirapine‐ versus efavirenz‐based highly active antiretroviral therapy regimens in antiretroviral‐naïve patients with advanced HIV infectionHIV Medicine, 2004
- Co-administration of rifampin and nevirapine in HIV-infected patients with tuberculosisAIDS, 2003
- Rifampin and Rifabutin Drug InteractionsArchives of internal medicine (1960), 2002
- Pharmacokinetic Interaction Between Nevirapine and Rifampicin in HIV-Infected Patients With TuberculosisJAIDS Journal of Acquired Immune Deficiency Syndromes, 2001
- High exposure to nevirapine in plasma is associated with an improved virological response in HIV-1-infected individualsAIDS, 2001